In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS and Solvay Pharmaceuticals develop obesity compound

Executive Summary

Bristol-Myers Squibb and Solvay Pharmaceuticals BV (cardiology, gastroenterology, mental health, and hormone replacement therapies) will jointly develop and globally commercialize Solvay's compound SLV319 for obesity and other metabolic disorders.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

UsernamePublicRestriction

Register